Upcoming IPO: Amanta Healthcare IPO Opens on September 1 - Check Issue Size & Key Details

Pharmaceutical company, Amanta Healthcare Ltd. is launching its Initial Public Offering (IPO) on September 1, 2025. Founded in 1994, Amanta Healthcare specialises in creating, producing, and selling sterile liquid formulations and medical devices. 

The bidding window for the Amanta Healthcare IPO will be open till September 3, 2025, for public subscription. The allotment process is expected to be finalised on September 4, 2025, and the company’s shares will be listed on both BSE and NSE. The tentative listing date is fixed as September 9, 2025.

Amanta Healthcare - IPO Details

Amanta Healthcare will be a bookbuilding consisting entirely of a fresh issue of 1 crore equity shares, aggregating up to ₹126 crores. The issue price band is set at ₹120 to ₹126 per share. The minimum lot size for an application is 119, and the minimum investment amount required for a retail investor is ₹14,994 (119 shares).

Beeline Capital Advisors Pvt. Ltd. is the book running lead manager, and MUFG Intime India Pvt. Ltd. is the registrar for the Amanta Healthcare IPO.

Check out newly Listed IPOs on BSE and NSE.

Utilisation of Proceeds

The Company will utilise the net proceeds from the issue for the following purposes:

• Funding capital expenditure requirements for civil construction work and towards the purchase of equipment, plant and machinery for setting up a new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat.
• Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up a new manufacturing line for SVP at Hariyala, Kheda, Gujarat.
• General Corporate Purposes.

Explore other Upcoming IPOs on BSE and NSE.

About Amanta Healthcare Ltd

Amanta Healthcare Ltd., founded in 1994 in Ahmedabad, is a pharmaceutical company that manufactures sterile liquid medicines, including injections, eye drops, respiratory solutions, and irrigation fluids. It utilises advanced technologies, such as Blow-Fill-Seal (BFS), to ensure high quality.

The company has a wide portfolio of over 45 generic medicines, supplied in India and abroad. Its large manufacturing facility in Gujarat is WHO-GMP certified and equipped with modern production lines for both large and small-volume injectables. In FY25, Amanta recorded a revenue of ₹276 crore with a net profit of ₹10.5 crore.